Link to this page
Minimum PDDI Information Ontology
Last uploaded:
October 17, 2023
Jump to:
| Id | http://purl.obolibrary.org/obo/MPIO_0000005
http://purl.obolibrary.org/obo/MPIO_0000005
|
|---|---|
| Preferred Name | mechanism of interaction information |
| Definitions |
An information content entity that is about the process or processes by which a drug-drug interaction clinical consequence occurs
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| label | mechanism of interaction information
|
|---|---|
| prefLabel | mechanism of interaction information
|
| prefixIRI | MPIO:0000005
|
| textual definition | An information content entity that is about the process or processes by which a drug-drug interaction clinical consequence occurs
|
| subClassOf | |
| type | |
| example of usage | Timolol is a nonselective beta-blocker, and timolol eye drops have been shown to produce systemic beta-blockade. Timolol is metabolized by CYP2D6, and patients who are deficient in CYP2D6 (PMs) have been shown to develop higher timolol plasma concentrations following timolol ophthalmic aqueous drops.
Non-steroidal anti-inflammatory drugs (NSAIDs) have antiplatelet effects which increase the bleeding risk when combined with oral anticoagulants such as warfarin. The antiplatelet effect of NSAIDs lasts only as long as the NSAID is present in the circulation, unlike aspirin’s antiplatelet effect, which lasts for up to 2 weeks after aspirin is discontinued.
|
| is about | |
| MPIO user-centered definition | An assertion about the process or the processes by which a drug-drug interaction clinical consequence occurs.
|
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |